Giaccia Amato 4
4 · Aravive, Inc. · Filed Mar 22, 2021
Insider Transaction Report
Form 4
Aravive, Inc.ARAV
Giaccia Amato
Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2021-03-19$0.06/sh+8,055$483→ 949,935 total - Exercise/Conversion
Common Stock
2021-03-19$0.06/sh+4,028$242→ 953,963 total - Exercise/Conversion
Stock Option (Right to buy)
2021-03-19−8,055→ 0 totalExercise: $0.06From: 2018-10-12Exp: 2021-04-25→ Common Stock (8,055 underlying) - Gift
Common Stock
2021-03-19−12,083→ 941,880 total - Exercise/Conversion
Stock Option (Right to buy)
2021-03-19−4,028→ 0 totalExercise: $0.06From: 2018-10-12Exp: 2021-04-25→ Common Stock (4,028 underlying)
Footnotes (2)
- [F1]This transaction involved a gift of securities by the reporting person to The Denise Chan Cancer Biology Program Endowed Fund in the Stanford Cancer Institute in the School of Medicine.
- [F2]On April 26, 2011, the reporting person was granted certain options to purchase shares of common stock at an exercise price of $0.02 per share. Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018 (the "Merger Agreement"), these options were converted into options to purchase an aggregate of 12,083 (8,055 and 4,028) shares of common stock (as adjusted a stock split) of Aravive, Inc. at a per share exercise price of $0.06 per share (as adjusted for a stock split). The options were fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger described in the Merger Agreement.